MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

13.81 0.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.74

Máximo

13.86

Indicadores-chave

By Trading Economics

Rendimento

-14M

-25M

Vendas

-5.5M

66M

EPS

-0.2

Margem de lucro

-38.059

Funcionários

342

EBITDA

-14M

-19M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+54.72% upside

Dividendos

By Dow Jones

Próximos Ganhos

13 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-145M

1.7B

Abertura anterior

13.66

Fecho anterior

13.81

Sentimento de Notícias

By Acuity

34%

66%

62 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jul. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 15:57 UTC

Conversa de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 de jul. de 2025, 15:49 UTC

Conversa de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Received All Required Authorizations

4 de jul. de 2025, 15:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Agreement Was Announced on Dec. 19

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 de jul. de 2025, 15:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 de jul. de 2025, 14:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 de jul. de 2025, 13:53 UTC

Conversa de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de jul. de 2025, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 de jul. de 2025, 12:30 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 de jul. de 2025, 12:15 UTC

Conversa de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 de jul. de 2025, 12:13 UTC

Conversa de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 de jul. de 2025, 12:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

54.72% parte superior

Previsão para 12 meses

Média 21.29 USD  54.72%

Máximo 29 USD

Mínimo 19 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

62 / 375 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.